GSK and Vir Biotechnology enter collaboration to find coronavirus solutions | GSK
gsk.com · 1,275 words · saved by 1 readers
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.
06 April 2020 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions For media and investors only Issued: London, UK and San Francisco, US Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months GSK to make equity investment of $250 million in Vir GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agre
related reading
- Scientists make breakthrough towards ‘universal’ antiviral drugsgavi.org
- Interceptinterceptfund.com
- Nature Biotechnology’s academic spinouts of 2019nature.com
- Paving the way for agents in biology \ Anthropicanthropic.com
- What We Learned Doing Fast Grants | Futurefuture.a16z.com
- The trinity of COVID-19: immunity, inflammation and interventionnature.com
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- GlaxoSmithKline and Sanofi report strong results in trials of Covid vaccine | GSK | The Guardiantheguardian.com
- *Reflective Disequilibrium*: Envisioning a world immune to global catastrophic biological risksreflectivedisequilibrium.blogspot.com
- How antiviral pill molnupiravir shot ahead in the COVID drug huntnature.com
- Company | GSKgsk.com
- Bill Gates explains “How to Prevent the Next Pandemic”economist.com